ファーマコゲノミクス技術の世界市場：市場規模・シェア・動向分析 (治療領域別・技術別・地域別)、セグメント別予測 (2025年～2030年)

ファーマコゲノミクス技術市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界のファーマコゲノミクス技術市場は2030年までに123億8,000万米ドルに達すると予測され、2025年から2030年にかけてCAGR 8.1％で拡大すると予測されています。

診断学はファーマコゲノミクス検査の台頭に適応しており、それに続いて新たな生物学的治療が追加されています。これらの検査は費用対効果の高い治療を可能にし、医薬品開発プロセスにも付加価値を与えます。疾患リスク予測、患者層別化、治療反応モニタリングなど、これらの検査の使用に関連する利点は、従来の方法と比較して、このファーマコゲノミクス・コンパニオン診断市場の重要な進歩の源になると予想されます。

さらに、ファーマコゲノミクス検査製品は、患者の治療レジメンの個別化と最適化において医師を支援します。ファーマコゲノミクスとセラノスティクスは統合医療への道を開いています。この特殊な分子診断検査群の急速な進化は、疾患のリアルタイム治療評価の改善に寄与しています。

しかし、ファーマコゲノミクスに基づく検査を医薬品開発スケジュールに早期に統合し、同時に承認を得るための課題が存在することが、成長の妨げになると予想されます。与えられた治療による個人差や集団差を特定するための臨床試験の適切な設計と実施は、セラノスティクスの成功に必要な特性となっています。

ファーマコゲノミクス技術市場：分析概要

• がん領域が2024年に40%近いシェアを占め、治療分野セグメントを支配。
• プレシジョン・オンコロジーの研究者は、複数の薬剤をさまざまに組み合わせて使用し、腫瘍の成長を単に遅らせるのではなく、腫瘍を消滅させることを目指しています。
• セラノスティクスの技術に関しては、ポリメラーゼ連鎖反応（PCR）が市場を独占しています。PCR技術は、その多くの利点から臨床診断に広く使用されており、この分野の重要な手法となっています。
• 北米地域がファーマコゲノミクス技術市場を独占しているのは、医薬品開発者が自社製品を診断薬と組み合わせるための経済的インセンティブがあるためです。
• アジア太平洋地域は、企業が未開拓のビジネスチャンスの獲得に取り組んでいることから、予測期間中に最も速い成長を示すと予測されています。
• ファーマコゲノミクス技術市場で事業を展開する主要企業には、QIAGEN、GE HealthCare、Agilent Technologies, Inc.、F. Hoffmann-La Roche Ltd.、FOUNDATION MEDICINE, INC.、Oxford Nanopore Technologies plc.、Twist Bioscience、Thermo Fisher Scientific Inc.、Leica Biosystems Nussloch GmBH、Pfizer Inc.、Abbottなどがあります。
• FOUNDATION MEDICINE, INC.は2024年11月、米国食品医薬品局（FDA）がFoundationOne Liquid CDxを、TEPMETKO（エルロチニブ）による治療の対象となる非小細胞肺がん（NSCLC）においてMETエクソン14スキップの変化を有する患者を同定するためのパートナー診断薬として承認したと発表しました。この血液ベースの検査は、標的治療の決定を支援し、薬理ゲノミクス・プロファイリングを通じてプレシジョン・オンコロジーをサポートします。

目次

第1章 分析方法・範囲

第2章 エグゼクティブサマリー

第3章 ファーマコゲノミクス技術市場：変動要因・傾向・範囲

• 市場連関の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場力学
  • 市場促進要因の分析
  • 市場抑制要因の分析
• ファーマコゲノミクス技術市場：分析ツール
  • 業界分析：ポーターのファイブフォース分析
  • PESTEL分析

第4章 ファーマコゲノミクス技術市場：治療領域別の推定・動向分析

• 治療領域別のダッシュボード
• ファーマコゲノミクス技術市場：治療領域別の変動分析
• 世界のファーマコゲノミクス技術市場：市場規模の予測と動向分析、治療領域別 (2018～2030年)
• 腫瘍
  • 市場の推定・予測（2018～2030年）
  • 肺がん
  • 乳がん
  • 大腸がん
  • 子宮頸がん
  • その他
• 神経疾患
  • 市場の推定・予測（2018～2030年）
• 心血管疾患
  • 市場の推定・予測（2018～2030年）
• 免疫疾患
  • 市場の推定・予測（2018～2030年）
• 感染症
  • 市場の推定・予測（2018～2030年）
• その他
  • 市場の推定・予測（2018～2030年）

第5章 ファーマコゲノミクス技術市場：技術別の推定・動向分析

• 技術別のダッシュボード
• ファーマコゲノミクス技術市場：技術別の変動分析
• 世界のファーマコゲノミクス技術市場：市場規模の予測と動向分析、技術別 (2018～2030年)
• PCR
• in situ ハイブリダイゼーション
• 免疫組織化学
• シーケンシング
• その他

第6章 ファーマコゲノミクス技術市場：地域別の推定・動向分析

• 市場ダッシュボード：地域別
• 市場シェア分析：地域別（2024年・2030年）
• ファーマコゲノミクス技術市場：主なポイント、地域別
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • ノルウェー
  • スウェーデン
  • デンマーク
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • タイ
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第7章 競合情勢

• 最近の動向と影響分析：主要市場参入企業別
• 企業/競合の分類
• ベンダー情勢
  • 主要企業のヒートマップ分析（2024年）
• 企業プロファイル
  • QIAGEN
  • GE HealthCare
  • Agilent Technologies, Inc.
  • F. Hoffmann-La Roche Ltd
  • FOUNDATION MEDICINE, INC
  • Thermo Fisher Scientific Inc.
  • Oxford Nanopore Technologies plc.
  • Twist Bioscience
  • Leica Biosystems Nussloch GmBH
  • Pfizer Inc
  • Abbott

List of Tables

• Table 1. List of abbreviations
• Table 2. Global pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 3. Global pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
• Table 4. Global pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
• Table 5. North America pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 6. North America pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
• Table 7. North America pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
• Table 8. U.S. laboratory pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 9. U.S. pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
• Table 10. U.S. pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
• Table 11. Canada pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 12. Canada pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
• Table 13. Canada pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
• Table 14. Mexico pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 15. Mexico pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
• Table 16. Mexico pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
• Table 17. Europe pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 18. Europe pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
• Table 19. Europe pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
• Table 20. Germany pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 21. Germany pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
• Table 22. Germany pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
• Table 23. UK pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 24. UK pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
• Table 25. UK pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
• Table 26. France pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 27. France pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
• Table 28. France pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
• Table 29. Italy pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 30. Italy pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
• Table 31. Italy pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
• Table 32. Spain pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 33. Spain pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
• Table 34. Spain pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
• Table 35. Denmark pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 36. Denmark pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
• Table 37. Denmark pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
• Table 38. Sweden pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 39. Sweden pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
• Table 40. Sweden pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
• Table 41. Norway pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 42. Norway laboratory proficiency testing market, by technology, 2018 - 2030 (USD Million)
• Table 43. Norway pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
• Table 44. Asia Pacific pharmacogenomics technology market, therapeutic area, 2018 - 2030 (USD Million)
• Table 45. Asia Pacific pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
• Table 46. Asia Pacific pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
• Table 47. China pharmacogenomics technology market, therapeutic area, 2018 - 2030 (USD Million)
• Table 48. China pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
• Table 49. China pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
• Table 50. Japan pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 51. Japan pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
• Table 52. Japan pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
• Table 53. India pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 54. India pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
• Table 55. India pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
• Table 56. South Korea pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 57. South Korea pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
• Table 58. South Korea pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
• Table 59. Australia pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 60. Australia pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
• Table 61. Australia pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
• Table 62. Thailand pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 63. Thailand pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
• Table 64. Thailand pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
• Table 65. Latin America pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 66. Latin America pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
• Table 67. Latin America pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
• Table 68. Brazil pharmacogenomics technology, therapeutic area, 2018 - 2030 (USD Million)
• Table 69. Brazil pharmacogenomics technology, by technology, 2018 - 2030 (USD Million)
• Table 70. Brazil pharmacogenomics technology, by region, 2018 - 2030 (USD Million)
• Table 71. Argentina pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 72. Argentina pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
• Table 73. Argentina pharmacogenomics technology market, by end region, 2018 - 2030 (USD Million)
• Table 74. MEA pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 75. MEA pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
• Table 76. MEA pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
• Table 77. South Africa pharmacogenomics technology testing market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 78. South Africa pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
• Table 79. South Africa pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
• Table 80. Saudi Arabia pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 81. Saudi Arabia pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
• Table 82. Saudi Arabia pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
• Table 83. UAE pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 84. UAE pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
• Table 85. UAE pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)
• Table 86. Kuwait pharmacogenomics technology market, by therapeutic area, 2018 - 2030 (USD Million)
• Table 87. Kuwait pharmacogenomics technology market, by technology, 2018 - 2030 (USD Million)
• Table 88. Kuwait pharmacogenomics technology market, by region, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Primary interviews
• Fig. 5 Market research approaches
• Fig. 6 Value-chain-based sizing & forecasting
• Fig. 7 QFD modeling for market share assessment
• Fig. 8 Market formulation & validation
• Fig. 9 Pharmacogenomics technology: market outlook
• Fig. 10 Pharmacogenomics technology: competitive insights
• Fig. 11 Parent market outlook
• Fig. 12 Related/ancillary market outlook
• Fig. 13 Penetration and growth prospect mapping
• Fig. 14 Industry value chain analysis
• Fig. 15 Pharmacogenomics technology market driver impact
• Fig. 16 Pharmacogenomics technology market restraint impact
• Fig. 17 Pharmacogenomics technology market strategic initiatives analysis
• Fig. 18 Pharmacogenomics technology market: Therapeutic area analysis
• Fig. 19 Pharmacogenomics technology market: Therapeutic area outlook and key takeaways
• Fig. 20 Oncology market estimates and forecast, 2018 - 2030
• Fig. 21 Neurological disorders market estimates and forecast, 2018 - 2030
• Fig. 22 Cardiovascular diseases market estimates and forecast, 2018 - 2030
• Fig. 23 Immunological disorders market estimates and forecast, 2018 - 2030
• Fig. 24 Infectious diseases market estimates and forecast, 2018 - 2030
• Fig. 25 Others market estimates and forecast, 2018 - 2030
• Fig. 26 Pharmacogenomics technology market: Technology movement analysis
• Fig. 27 Pharmacogenomics technology market: Technology outlook and key takeaways
• Fig. 28 PCR market estimates and forecasts, 2018 - 2030
• Fig. 29 In-situ hybridization market estimates and forecasts, 2018 - 2030
• Fig. 30 Immunohistochemistry market estimates and forecasts, 2018 - 2030
• Fig. 31 Sequencing market estimates and forecasts, 2018 - 2030
• Fig. 32 Others market estimates and forecasts, 2018 - 2030
• Fig. 33 Global Pharmacogenomics technology market: Regional movement analysis
• Fig. 34 Global Pharmacogenomics technology market: Regional outlook and key takeaways
• Fig. 35 North America market estimates and forecasts, 2018 - 2030
• Fig. 36 U.S. market estimates and forecasts, 2018 - 2030
• Fig. 37 Canada market estimates and forecasts, 2018 - 2030
• Fig. 38 Mexico market estimates and forecasts, 2018 - 2030
• Fig. 39 Europe market estimates and forecasts, 2018 - 2030
• Fig. 40 UK market estimates and forecasts, 2018 - 2030
• Fig. 41 Germany market estimates and forecasts, 2018 - 2030
• Fig. 42 France market estimates and forecasts, 2018 - 2030
• Fig. 43 Italy market estimates and forecasts, 2018 - 2030
• Fig. 44 Spain market estimates and forecasts, 2018 - 2030
• Fig. 45 Denmark market estimates and forecasts, 2018 - 2030
• Fig. 46 Sweden market estimates and forecasts, 2018 - 2030
• Fig. 47 Norway market estimates and forecasts, 2018 - 2030
• Fig. 48 Asia Pacific market estimates and forecasts, 2018 - 2030
• Fig. 49 China market estimates and forecasts, 2018 - 2030
• Fig. 50 Japan market estimates and forecasts, 2018 - 2030
• Fig. 51 India market estimates and forecasts, 2018 - 2030
• Fig. 52 Thailand market estimates and forecasts, 2018 - 2030
• Fig. 53 South Korea market estimates and forecasts, 2018 - 2030
• Fig. 54 Australia market estimates and forecasts, 2018 - 2030
• Fig. 55 Latin America market estimates and forecasts, 2018 - 2030
• Fig. 56 Brazil market estimates and forecasts, 2018 - 2030
• Fig. 57 Argentina market estimates and forecasts, 2018 - 2030
• Fig. 58 Middle East and Africa market estimates and forecasts, 2018 - 2030
• Fig. 59 South Africa market estimates and forecasts, 2018 - 2030
• Fig. 60 Saudi Arabia market estimates and forecasts, 2018 - 2030
• Fig. 61 UAE market estimates and forecasts, 2018 - 2030
• Fig. 62 Kuwait market estimates and forecasts, 2018 - 2030

Pharmacogenomics Technology Market Growth & Trends:

The global pharmacogenomics technology market is anticipated to reach USD 12.38 billion by 2030 and is anticipated to expand at a CAGR of 8.1% from 2025 to 2030, according to a new report by Grand View Research, Inc. Diagnostics is adapting to the rise of pharmacogenomic tests, which are followed by the addition of new biological treatments. These tests enable cost-effective treatment and also add value to the process of drug development. Advantages associated with the usage of these tests such as disease risk prediction, patient stratification, and therapeutic response monitoring over the traditional methods is anticipated to a significant source of progress in this pharmacogenomics companion diagnostics market.

In addition, pharmacogenomics testing products aid physicians in individualizing and optimization of the patient's therapeutic regimen. Pharmacogenomics and theranostics are paving the way for integrated medicine. Rapid evolution in this group of specialized molecular diagnostic tests is contributing to improvement for the assessment of real-time treatment of disease.

However, the presence of challenges pertaining to early integration of pharmacogenomic based testing into drug development timelines for gaining approval simultaneously is anticipated to impede growth. Proper designing and implementation of clinical trials in order to identify individual as well as population variations from a given therapy have become a necessary attribute for the success of theranostics.

Pharmacogenomics Technology Market Report Highlights:

• Oncology dominated the therapeutic area segment with nearly 40% share in 2024, driven by the presence of a substantial number of products
• Precision oncology researchers aim to use multiple medications in various combinations to eliminate tumors rather than merely slowing their growth
• Polymerase Chain Reaction (PCR) dominated the market the with respect to technology for theranostics. The PCR technique is widely used in clinical diagnostics due to its numerous advantages, making it a key method in the field.
• North American region dominates the pharmacogenomics technology market because of economic incentives for drug developers to pair their products with diagnostics
• Asia Pacific market is projected to showcase the fastest growth over the forecast period as the companies are engaged in capturing untapped opportunities
• Key players operating in the pharmacogenomics technology market include QIAGEN; GE HealthCare.; Agilent Technologies, Inc.; F. Hoffmann-La Roche Ltd; FOUNDATION MEDICINE, INC.; Oxford Nanopore Technologies plc.; Twist Bioscience.; Thermo Fisher Scientific Inc.; Leica Biosystems Nussloch GmBH; Pfizer Inc.; Abbott
• In November 2024, FOUNDATION MEDICINE, INC. announced that the U.S. Food and Drug Administration (FDA) had approved FoundationOne Liquid CDx as a partner diagnostic to identify patients with MET exon 14 skipping alterations in non-small cell lung cancer (NSCLC) eligible for treatment with TEPMETKO(erlotinib). This blood-based test helps guide targeted therapy decisions, supporting precision oncology through pharmacogenomic profiling.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Therapeutic area
  • 1.2.2. Technology
  • 1.2.3. Regional Scope
  • 1.2.4. Estimates and Forecasts Timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Therapeutic area outlook
  • 2.2.2. Technology outlook
  • 2.2.3. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Pharmacogenomics Technology Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
  • 3.2.2. Market restraint analysis
• 3.3. Pharmacogenomics Technology Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Pharmacogenomics Technology: Therapeutic Area Estimates & Trend Analysis

• 4.1. Therapeutic Area Dashboard
• 4.2. Pharmacogenomics Technology Market: Therapeutic Area Movement Analysis
• 4.3. Global Pharmacogenomics Technology Market Size & Trend Analysis, by Therapeutic Area, 2018 to 2030 (USD Million)
• 4.4. Oncology
  • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.2. Lung Cancer
    • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.3. Breast Cancer
    • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.4. Colorectal Cancer
    • 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.5. Cervical Cancer
    • 4.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.6. Others
    • 4.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Neurological Disorders
  • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. Cardiovascular Disorders
  • 4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. Immunological Disorders
  • 4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.8. Infectious Diseases
  • 4.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.9. Others
  • 4.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Pharmacogenomics Technology Market: Technology Estimates & Trend Analysis

• 5.1. Technology Segment Dashboard
• 5.2. Pharmacogenomics Technology Market: Technology Movement Analysis
• 5.3. Global Pharmacogenomics Technology Market Size & Trend Analysis, by Technology, 2018 to 2030 (USD Million)
• 5.4. PCR
  • 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. In-situ Hybridization
  • 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Immunohistochemistry
  • 5.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.7. Sequencing
  • 5.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.8. Others
  • 5.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Pharmacogenomics Technology Market: Regional Estimates & Trend Analysis

• 6.1. Regional Market Dashboard
• 6.2. Regional Market Share Analysis, 2024 & 2030
• 6.3. Pharmacogenomics Technology Market by Region: Key Takeaways
• 6.4. North America
  • 6.4.1. U.S.
    • 6.4.1.1. Key country dynamics
    • 6.4.1.2. Regulatory framework/ reimbursement structure
    • 6.4.1.3. Competitive scenario
    • 6.4.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.2. Canada
    • 6.4.2.1. Key country dynamics
    • 6.4.2.2. Regulatory framework/ reimbursement structure
    • 6.4.2.3. Competitive scenario
    • 6.4.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.3. Mexico
    • 6.4.3.1. Key country dynamics
    • 6.4.3.2. Regulatory framework/ reimbursement structure
    • 6.4.3.3. Competitive scenario
    • 6.4.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Europe
  • 6.5.1. UK
    • 6.5.1.1. Key country dynamics
    • 6.5.1.2. Regulatory framework/ reimbursement structure
    • 6.5.1.3. Competitive scenario
    • 6.5.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.2. Germany
    • 6.5.2.1. Key country dynamics
    • 6.5.2.2. Regulatory framework/ reimbursement structure
    • 6.5.2.3. Competitive scenario
    • 6.5.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.3. France
    • 6.5.3.1. Key country dynamics
    • 6.5.3.2. Regulatory framework/ reimbursement structure
    • 6.5.3.3. Competitive scenario
    • 6.5.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.4. Italy
    • 6.5.4.1. Key country dynamics
    • 6.5.4.2. Regulatory framework/ reimbursement structure
    • 6.5.4.3. Competitive scenario
    • 6.5.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.5. Spain
    • 6.5.5.1. Key country dynamics
    • 6.5.5.2. Regulatory framework/ reimbursement structure
    • 6.5.5.3. Competitive scenario
    • 6.5.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.6. Norway
    • 6.5.6.1. Key country dynamics
    • 6.5.6.2. Regulatory framework/ reimbursement structure
    • 6.5.6.3. Competitive scenario
    • 6.5.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.7. Sweden
    • 6.5.7.1. Key country dynamics
    • 6.5.7.2. Regulatory framework/ reimbursement structure
    • 6.5.7.3. Competitive scenario
    • 6.5.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.8. Denmark
    • 6.5.8.1. Key country dynamics
    • 6.5.8.2. Regulatory framework/ reimbursement structure
    • 6.5.8.3. Competitive scenario
    • 6.5.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Asia Pacific
  • 6.6.1. Japan
    • 6.6.1.1. Key country dynamics
    • 6.6.1.2. Regulatory framework/ reimbursement structure
    • 6.6.1.3. Competitive scenario
    • 6.6.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.2. China
    • 6.6.2.1. Key country dynamics
    • 6.6.2.2. Regulatory framework/ reimbursement structure
    • 6.6.2.3. Competitive scenario
    • 6.6.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.3. India
    • 6.6.3.1. Key country dynamics
    • 6.6.3.2. Regulatory framework/ reimbursement structure
    • 6.6.3.3. Competitive scenario
    • 6.6.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.4. Australia
    • 6.6.4.1. Key country dynamics
    • 6.6.4.2. Regulatory framework/ reimbursement structure
    • 6.6.4.3. Competitive scenario
    • 6.6.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.5. South Korea
    • 6.6.5.1. Key country dynamics
    • 6.6.5.2. Regulatory framework/ reimbursement structure
    • 6.6.5.3. Competitive scenario
    • 6.6.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.6. Thailand
    • 6.6.6.1. Key country dynamics
    • 6.6.6.2. Regulatory framework/ reimbursement structure
    • 6.6.6.3. Competitive scenario
    • 6.6.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 6.7. Latin America
  • 6.7.1. Brazil
    • 6.7.1.1. Key country dynamics
    • 6.7.1.2. Regulatory framework/ reimbursement structure
    • 6.7.1.3. Competitive scenario
    • 6.7.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.2. Argentina
    • 6.7.2.1. Key country dynamics
    • 6.7.2.2. Regulatory framework/ reimbursement structure
    • 6.7.2.3. Competitive scenario
    • 6.7.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 6.8. MEA
  • 6.8.1. South Africa
    • 6.8.1.1. Key country dynamics
    • 6.8.1.2. Regulatory framework/ reimbursement structure
    • 6.8.1.3. Competitive scenario
    • 6.8.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.8.2. Saudi Arabia
    • 6.8.2.1. Key country dynamics
    • 6.8.2.2. Regulatory framework/ reimbursement structure
    • 6.8.2.3. Competitive scenario
    • 6.8.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.8.3. UAE
    • 6.8.3.1. Key country dynamics
    • 6.8.3.2. Regulatory framework/ reimbursement structure
    • 6.8.3.3. Competitive scenario
    • 6.8.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.8.4. Kuwait
    • 6.8.4.1. Key country dynamics
    • 6.8.4.2. Regulatory framework/ reimbursement structure
    • 6.8.4.3. Competitive scenario
    • 6.8.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Company/Competition Categorization
• 7.3. Vendor Landscape
  • 7.3.1. Key company heat map analysis, 2024
• 7.4. Company Profiles
  • 7.4.1. QIAGEN
    • 7.4.1.1. Company overview
    • 7.4.1.2. Financial performance
    • 7.4.1.3. Product benchmarking
    • 7.4.1.4. Strategic initiatives
  • 7.4.2. GE HealthCare
    • 7.4.2.1. Company overview
    • 7.4.2.2. Financial performance
    • 7.4.2.3. Product benchmarking
    • 7.4.2.4. Strategic initiatives
  • 7.4.3. Agilent Technologies, Inc.
    • 7.4.3.1. Company overview
    • 7.4.3.2. Financial performance
    • 7.4.3.3. Product benchmarking
    • 7.4.3.4. Strategic initiatives
  • 7.4.4. F. Hoffmann-La Roche Ltd
    • 7.4.4.1. Company overview
    • 7.4.4.2. Financial performance
    • 7.4.4.3. Product benchmarking
    • 7.4.4.4. Strategic initiatives
  • 7.4.5. FOUNDATION MEDICINE, INC
    • 7.4.5.1. Company overview
    • 7.4.5.2. Financial performance
    • 7.4.5.3. Product benchmarking
    • 7.4.5.4. Strategic initiatives
  • 7.4.6. Thermo Fisher Scientific Inc.
    • 7.4.6.1. Company overview
    • 7.4.6.2. Financial performance
    • 7.4.6.3. Product benchmarking
    • 7.4.6.4. Strategic initiatives
  • 7.4.7. Oxford Nanopore Technologies plc.
    • 7.4.7.1. Company overview
    • 7.4.7.2. Financial performance
    • 7.4.7.3. Product benchmarking
    • 7.4.7.4. Strategic initiatives
  • 7.4.8. Twist Bioscience
    • 7.4.8.1. Company overview
    • 7.4.8.2. Financial performance
    • 7.4.8.3. Product benchmarking
    • 7.4.8.4. Strategic initiatives
  • 7.4.9. Leica Biosystems Nussloch GmBH
    • 7.4.9.1. Company overview
    • 7.4.9.2. Financial performance
    • 7.4.9.3. Product benchmarking
    • 7.4.9.4. Strategic initiatives
  • 7.4.10. Pfizer Inc
    • 7.4.10.1. Company overview
    • 7.4.10.2. Financial performance
    • 7.4.10.3. Product benchmarking
    • 7.4.10.4. Strategic initiatives
  • 7.4.11. Abbott
    • 7.4.11.1. Company overview
    • 7.4.11.2. Financial performance
    • 7.4.11.3. Product benchmarking
    • 7.4.11.4. Strategic initiatives